Your browser doesn't support javascript.
loading
Failure of primary atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients.
Gajurel, K; Gomez, C A; Dhakal, R; Vogel, H; Montoya, J G.
Afiliação
  • Gajurel K; Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, California, USA.
  • Gomez CA; Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, California, USA.
  • Dhakal R; Toxoplasma Serology Laboratory, National Reference Center for the Study and Diagnosis of Toxoplasmosis, Palo Alto, California, USA.
  • Vogel H; Department of Pathology, School of Medicine, Stanford University, Stanford, California, USA.
  • Montoya JG; Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, California, USA.
Transpl Infect Dis ; 18(3): 446-452, 2016 Jun.
Article em En | MEDLINE | ID: mdl-27016655
ABSTRACT
The efficacy of primary prophylaxis with atovaquone in preventing Toxoplasma reactivation and disease in hematopoietic cell transplant (HCT) recipients is unknown. We describe 2 cases of atovaquone prophylaxis failure in pre-HCT Toxoplasma-seropositive (pre-HCTSP) recipients who underwent allogeneic HCT (allo-HCT) and review the literature on atovaquone prophylaxis in HCT recipients.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article